scholarly journals Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks

2021 ◽  
Vol Volume 14 ◽  
pp. 457-465
Author(s):  
Amanda Cheung ◽  
Aijaz Ahmed
PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88569 ◽  
Author(s):  
Giorgio Sesti ◽  
Teresa Vanessa Fiorentino ◽  
Franco Arturi ◽  
Maria Perticone ◽  
Angela Sciacqua ◽  
...  

2018 ◽  
Vol 39 (2) ◽  
pp. 342-352 ◽  
Author(s):  
James Paik ◽  
Pegah Golabi ◽  
Zahra Younoszai ◽  
Alita Mishra ◽  
Gregory Trimble ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
L. Orlić ◽  
I. Mikolasevic ◽  
Z. Bagic ◽  
S. Racki ◽  
D. Stimac ◽  
...  

Research in recent years has led to the recognition of the importance of nonalcoholic fatty liver disease (NAFLD) and its relationship to the metabolic syndrome (MS). This has led to a growing interest in the potential prognostic value of NAFLD for adverse cardiovascular disease (CVD) outcome. On the other hand, searching for new risk factors for chronic kidney disease (CKD) development and progression is very important. Growing evidence suggests that the MS is an important factor in the pathogenesis of CKD. The best confirmation of this pathogenic link is hypertensive and diabetic nephropathy as the main causes of CKD. Furthermore, the possible link between NAFLD and CKD has also attracted research interest and recent data suggest an association between these two conditions. These findings have fuelled concerns that NAFLD may be a new and added risk factor for the development and progression of CKD. NAFLD and CKD share some important cardiometabolic risk factors and possible common pathophysiological mechanisms, and both are linked to an increased risk of incident CVD events. Therefore, common factors underlying the pathogenesis of NAFLD and CKD may be insulin resistance, oxidative stress, activation of rennin-angiotensin system, and inappropriate secretion of inflammatory cytokines by steatotic and inflamed liver.


Diabetes Care ◽  
2014 ◽  
Vol 37 (6) ◽  
pp. 1729-1736 ◽  
Author(s):  
Giovanni Targher ◽  
Alessandro Mantovani ◽  
Isabella Pichiri ◽  
Lucia Mingolla ◽  
Valentina Cavalieri ◽  
...  

Antibiotics ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 780
Author(s):  
Lara Šamadan ◽  
Mia Jeličić ◽  
Adriana Vince ◽  
Neven Papić

Recurrent Clostridioides difficile infections (rCDI) have a substantial impact on healthcare systems, with limited and often expensive therapeutic options. Nonalcoholic fatty liver disease (NAFLD) affects about 25% of the adult population and is associated with metabolic syndrome, changes in gut microbiome and bile acids biosynthesis, all possibly related with rCDI. The aim of this study was to determine whether NAFLD is a risk factor associated with rCDI. A retrospective cohort study included patients ≥ 60 years hospitalized with CDI. The cohort was divided into two groups: those who were and were not readmitted with CDI within 3 months of discharge. Of the 329 patients included, 107 patients (32.5%) experienced rCDI. Patients with rCDI were older, had higher Charlson Age–Comorbidity Index (CACI) and were more frequently hospitalized within 3 months. Except for chronic kidney disease and NAFLD, which were more frequent in the rCDI group, there were no differences in other comorbidities, antibiotic classes used and duration of antimicrobial therapy. Multivariable Cox regression analysis showed that age >75 years, NAFLD, CACI >6, chronic kidney disease, statins and immobility were associated with rCDI. In conclusion, our study identified NAFLD as a possible new host-related risk factor associated with rCDI.


Sign in / Sign up

Export Citation Format

Share Document